Identification
NameTelavancin
Accession NumberDB06402
TypeSmall Molecule
GroupsApproved
Description

Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.

Structure
Thumb
Synonyms
Telavancina
Télavancine
Telavancinum
External IDs Not Available
Product Ingredients
IngredientUNIICASInChI KeyDetails
Telavancin hydrochloride0701472ZG0 560130-42-9GSSIWSIRBWAZHG-ACOPVEIWSA-NDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
VibativInjection, powder, lyophilized, for solution15 mg/mLIntravenousTheravance, Inc.2009-11-05Not applicableUs
VibativPowder, for solution750 mgIntravenousPendopharm Division Of De Pharmascience Inc2016-01-06Not applicableCanada
VibativInjection, powder, lyophilized, for solution15 mg/mLIntravenousTheravance, Inc.2009-11-05Not applicableUs
VibativInjection, powder, lyophilized, for solution15 mg/mLIntravenousTheravance Biopharma R&d, Inc.2009-11-05Not applicableUs
VibativPowder, for solution250 mgIntravenousPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
VibativInjection, powder, lyophilized, for solution15 mg/mLIntravenousTheravance Biopharma R&d, Inc.2009-11-05Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIXK134822Z0
CAS number372151-71-8
WeightAverage: 1755.65
Monoisotopic: 1753.6374296
Chemical FormulaC80H106Cl2N11O27P
InChI KeyONUMZHGUFYIKPM-MXNFEBESSA-N
InChI
InChI=1S/C80H106Cl2N11O27P/c1-7-8-9-10-11-12-13-14-21-85-22-23-87-80(5)32-57(115-37(4)71(80)103)119-70-68(102)67(101)55(34-94)118-79(70)120-69-53-28-41-29-54(69)117-52-20-17-40(27-46(52)82)65(99)63-77(109)91-61(78(110)111)43-30-50(96)44(33-86-35-121(112,113)114)66(100)58(43)42-25-38(15-18-49(42)95)59(74(106)93-63)90-75(107)60(41)89-73(105)48(31-56(83)97)88-76(108)62(92-72(104)47(84-6)24-36(2)3)64(98)39-16-19-51(116-53)45(81)26-39/h15-20,25-30,36-37,47-48,55,57,59-65,67-68,70-71,79,84-87,94-96,98-103H,7-14,21-24,31-35H2,1-6H3,(H2,83,97)(H,88,108)(H,89,105)(H,90,107)(H,91,109)(H,92,104)(H,93,106)(H,110,111)(H2,112,113,114)/t37-,47+,48-,55+,57-,59+,60+,61-,62+,63-,64+,65+,67+,68-,70+,71+,79-,80-/m0/s1
IUPAC Name
(1S,2R,18R,19R,22S,25R,28R,40S)-22-(carbamoylmethyl)-5,47-dichloro-48-{[(2S,3R,4S,5S,6R)-3-{[(2S,4S,5S,6S)-4-{[2-(decylamino)ethyl]amino}-5-hydroxy-4,6-dimethyloxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2,18,32,35,37-pentahydroxy-19-[(2R)-4-methyl-2-(methylamino)pentanamido]-20,23,26,42,44-pentaoxo-36-{[(phosphonomethyl)amino]methyl}-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2^{3,6}.2^{14,17}.1^{8,12}.1^{29,33}.0^{10,25}.0^{34,39}]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
SMILES
CCCCCCCCCCNCCN[C@@]1(C)C[[email protected]](O[C@@H]2[C@@H](O)[[email protected]](O)[C@@H](CO)O[[email protected]]2OC2=C3OC4=CC=C(C=C4Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]4C(C=C2OC2=C(Cl)C=C(C=C2)[C@@H](O)[C@@H]2NC(=O)[[email protected]](NC4=O)C4=CC(=C(O)C=C4)C4=C(O)C(CNCP(O)(O)=O)=C(O)C=C4[[email protected]](NC2=O)C(O)=O)=C3)O[C@@H](C)[[email protected]]1O
Pharmacology
Indication

For the treatment of complicated skin and skin structure infections (cSSSI) caused by gram-positive bacteria like methicillin-susceptible or -resistant Staphylococcus aureus, vancomycin-susceptible Enterococcus faecalis, and Streptococcus pyogenes, Streptococcus agalactiae, or Streptococcus anginosus group. Also for the treatment of adult patients with hospital-acquired bacterial pneumonia (HAP) and ventilator-associated bacterial pneumonia (VAP), known or suspected to be caused by susceptible isolates of Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant S. aureus).

Structured Indications
Pharmacodynamics

Telavancin is a semi-synthetic derivative of vancomycin, therefore the mode of bactericidal action is similar to vancomycin in which both antibiotics inhibit cell wall synthesis. Not only that, it displays concentration-dependent bactericidal action. Furthermore, telavancin is a more potent inhibitor (10-fold) of peptidoglycan synthesis and, unlike vancomycin, disrupts cell membrane integrity via its interaction with lipid II. AUC/MIC ratio best predicts the extent of in-vivo response in which the higher the ratio, the greater the bactericidal activity. The smallest ratio in which one would be able to observe no bacterial growth at 24 hours is 50. Maximal bactericidal activity is observed at a AUC/MIC ratio of 404.

Mechanism of action

Telavancin is a bactericidal lipoglycopeptide that is active against a broad range of gram-positive bacteria. Telavancin prevents polymerization of N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) and cross-linking of peptidoglycan by binding to D-Ala-D-Ala. As a result, inhibition of bacterial cell wall synthesis occurs. Furthermore, telavancin disrupts membrane potential and cell permeability as a result of the lipophillic side chain moiety. This additional bactericidal mechanism is what sets telavancin apart from vancomycin.

Related Articles
Absorption

Telavancin demonstrates linear pharmacokinetics at doses between 1 and 12.5 mg/kg. Furthermore, 24 hours post-infusion of a dose of 7.5 to 15 mg/kg, activity against MRSA and penicillin-resistant Streptococcus pneumonia can still be observed. The trough concentration at this point of time is approximately 10 μg/mL. Telavancin also has poor bioavailability and must be administered over 30-120 minutes IV. Cmax, healthy subjects, 10 mg/kg = 93.6 ± 14.2 μg/mL; AUC (0- ∞), healthy subjects, 10 mg/kg = 747 ± 129 μg · h/mL; AUC (0-24h), healthy subjects, 10 mg/kg = 666± 107 μg · h/mL; Time to steady state = 3 days;

Volume of distribution

Vss, healthy subjects, 10 mg/kg = 0.14 L/kg

Protein binding

>90% to serum albumin in a concentration independent manner (despite being highly protein bound, antimicrobial activity of telavancin is not affected)

Metabolism

Metabolism of telavancin does not involve the cytochrome P450 enzyme system. Primary metabolite is called THRX-651540, but the metabolite pathway has not been identified.

SubstrateEnzymesProduct
Telavancin
Not Available
THRX-651540Details
Route of elimination

Urine with >80% as unchanged drug and <20% as hydroxylated metabolites (with dose of 10mg/kg); Feces (<1%)

Half life

Terminal elimination half-life = 8 ± 1.5 hours (with normal renal function)

Clearance

Cl, healthy subjects, 10 mg/kg = 13.9 ± 2.9 mL/h/kg

ToxicityNot Available
Affected organisms
  • Streptococcus pyogenes
  • Streptococcus agalactiae
  • Staphylococcus aureus
  • Enterococcus faecalis
  • Streptococcus anginosus
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Telavancin.Approved
AmiodaroneTelavancin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Telavancin.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Telavancin.Approved
AnagrelideTelavancin may increase the QTc-prolonging activities of Anagrelide.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
Arsenic trioxideTelavancin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherTelavancin may increase the QTc-prolonging activities of Artemether.Approved
AsenapineTelavancin may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirAtazanavir may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Telavancin.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Telavancin.Approved
BedaquilineTelavancin may increase the QTc-prolonging activities of Bedaquiline.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
BuserelinBuserelin may increase the QTc-prolonging activities of Telavancin.Approved
CeritinibTelavancin may increase the QTc-prolonging activities of Ceritinib.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Telavancin.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Telavancin.Approved, Vet Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
CisaprideTelavancin may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramTelavancin may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Telavancin.Approved
ClomipramineClomipramine may increase the QTc-prolonging activities of Telavancin.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Telavancin.Approved
CrizotinibTelavancin may increase the QTc-prolonging activities of Crizotinib.Approved
DabrafenibDabrafenib may increase the QTc-prolonging activities of Telavancin.Approved
DasatinibDasatinib may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Telavancin.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Telavancin.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Telavancin.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Telavancin.Approved
DisopyramideTelavancin may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideTelavancin may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Telavancin.Approved
DomperidoneTelavancin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Telavancin.Approved
DronedaroneTelavancin may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Telavancin.Approved, Vet Approved
EliglustatTelavancin may increase the QTc-prolonging activities of Eliglustat.Approved
EribulinEribulin may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Telavancin.Approved, Vet Approved
EscitalopramTelavancin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Telavancin.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Telavancin.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Telavancin.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Telavancin.Approved, Withdrawn
FluconazoleFluconazole may increase the QTc-prolonging activities of Telavancin.Approved
FluoxetineTelavancin may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolTelavancin may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FormoterolFormoterol may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Telavancin.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Telavancin.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Telavancin.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
GoserelinGoserelin may increase the QTc-prolonging activities of Telavancin.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
HaloperidolHaloperidol may increase the QTc-prolonging activities of Telavancin.Approved
HeparinThe therapeutic efficacy of Heparin can be decreased when used in combination with Telavancin.Approved, Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Telavancin.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Telavancin.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
IbutilideTelavancin may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneTelavancin may increase the QTc-prolonging activities of Iloperidone.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Telavancin.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Telavancin.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Telavancin.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Telavancin.Approved, Vet Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Telavancin.Approved
ItraconazoleItraconazole may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Telavancin.Approved
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
LenvatinibTelavancin may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
LithiumLithium may increase the QTc-prolonging activities of Telavancin.Approved
LopinavirTelavancin may increase the QTc-prolonging activities of Lopinavir.Approved
LumefantrineTelavancin may increase the QTc-prolonging activities of Lumefantrine.Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Telavancin.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Telavancin.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Telavancin.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Telavancin.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Telavancin.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Telavancin.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Telavancin.Approved
MoexiprilMoexipril may increase the QTc-prolonging activities of Telavancin.Approved
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
NelfinavirNelfinavir may increase the QTc-prolonging activities of Telavancin.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Telavancin.Approved
NilotinibTelavancin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Telavancin.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Telavancin.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Telavancin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Telavancin.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Telavancin.Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Telavancin.Approved, Vet Approved
PaliperidoneTelavancin may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatTelavancin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParoxetineParoxetine may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Telavancin.Approved
PazopanibTelavancin may increase the QTc-prolonging activities of Pazopanib.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Telavancin.Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Telavancin.Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Telavancin.Approved
PimozideTelavancin may increase the QTc-prolonging activities of Pimozide.Approved
PosaconazolePosaconazole may increase the QTc-prolonging activities of Telavancin.Approved, Investigational, Vet Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Telavancin.Approved
ProcainamideTelavancin may increase the QTc-prolonging activities of Procainamide.Approved
PromazinePromazine may increase the QTc-prolonging activities of Telavancin.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Telavancin.Approved
PropafenonePropafenone may increase the QTc-prolonging activities of Telavancin.Approved
PropofolPropofol may increase the QTc-prolonging activities of Telavancin.Approved, Investigational, Vet Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Telavancin.Approved
QuetiapineTelavancin may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineTelavancin may increase the QTc-prolonging activities of Quinidine.Approved
QuinineTelavancin may increase the QTc-prolonging activities of Quinine.Approved
RanolazineRanolazine may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Telavancin.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Telavancin.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Telavancin.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
SertralineSertraline may increase the QTc-prolonging activities of Telavancin.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Telavancin.Approved, Vet Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Telavancin.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
SotalolTelavancin may increase the QTc-prolonging activities of Sotalol.Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Telavancin.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Telavancin.Approved, Vet Approved
SunitinibSunitinib may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Telavancin.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Telavancin.Approved
TetrabenazineTelavancin may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThioridazineTelavancin may increase the QTc-prolonging activities of Thioridazine.Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Telavancin.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Telavancin.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
ToremifeneTelavancin may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrazodoneTrazodone may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Telavancin.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Telavancin.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Telavancin.Approved, Vet Approved
VandetanibTelavancin may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Telavancin.Approved
VemurafenibTelavancin may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Telavancin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Telavancin.Approved
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Telavancin.Approved, Investigational
ZiprasidoneTelavancin may increase the QTc-prolonging activities of Ziprasidone.Approved
ZuclopenthixolTelavancin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Laohavaleeson S, Kuti JL, Nicolau DP: Telavancin: a novel lipoglycopeptide for serious gram-positive infections. Expert Opin Investig Drugs. 2007 Mar;16(3):347-57. [PubMed:17302529 ]
  2. Rubinstein E, Corey GR, Stryjewski ME, Kanafani ZA: Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia. Expert Opin Pharmacother. 2011 Dec;12(17):2737-50. doi: 10.1517/14656566.2011.633511. [PubMed:22077833 ]
  3. Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagace-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA: New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010 May 7;70(7):859-86. doi: 10.2165/11534440-000000000-00000. [PubMed:20426497 ]
  4. Wong SL, Goldberg MR, Ballow CH, Kitt MM, Barriere SL: Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. Pharmacotherapy. 2010 Feb;30(2):136-43. doi: 10.1592/phco.30.2.136. [PubMed:20099988 ]
External Links
ATC CodesJ01XA03
AHFS Codes
  • 8:12.28.16
PDB EntriesNot Available
FDA labelDownload (6.45 MB)
MSDSDownload (479 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableEnd Stage Renal Disease (ESRD) / Kidney Diseases1
1CompletedNot AvailableHealthy Volunteers1
2CompletedTreatmentAbscesses / Cellulitis / Infections, Gram-Positive Bacterial / Minor burns / Ulcers / Wound Infections1
2CompletedTreatmentBacteremia / Infection NOS1
2CompletedTreatmentInfections, Gram-Positive Bacterial2
3CompletedTreatmentPneumonia, Bacterial2
3CompletedTreatmentStaphylococcal Skin Infections2
3RecruitingTreatmentBacteremia1
4CompletedNot AvailableEnd-Stage Renal Disease (ESRD) / Stage 5 Chronic Kidney Diseases1
4Not Yet RecruitingOtherCystic Fibrosis (CF)1
4RecruitingBasic ScienceInfections, Gram-Positive Bacterial1
Not AvailableRecruitingNot AvailablePregnancy1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntravenous15 mg/mL
Powder, for solutionIntravenous250 mg
Powder, for solutionIntravenous750 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6635618 No2003-09-112023-09-11Us
US6858584 No2002-08-242022-08-24Us
US6872701 No2001-06-052021-06-05Us
US7008923 No2001-05-062021-05-06Us
US7208471 No2001-05-012021-05-01Us
US7351691 No2001-05-012021-05-01Us
US7531623 No2007-01-012027-01-01Us
US7544364 No2001-05-012021-05-01Us
US7700550 No2001-05-012021-05-01Us
US8101575 No2001-05-012021-05-01Us
US8158580 No2001-05-012021-05-01Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0148 mg/mLALOGPS
logP2.32ALOGPS
logP-6.2ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)1.55ChemAxon
pKa (Strongest Basic)9.99ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count29ChemAxon
Hydrogen Donor Count23ChemAxon
Polar Surface Area598.09 Å2ChemAxon
Rotatable Bond Count30ChemAxon
Refractivity429.41 m3·mol-1ChemAxon
Polarizability175.85 Å3ChemAxon
Number of Rings10ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9186
Blood Brain Barrier-0.9691
Caco-2 permeable-0.6403
P-glycoprotein substrateSubstrate0.9318
P-glycoprotein inhibitor INon-inhibitor0.6459
P-glycoprotein inhibitor IINon-inhibitor0.9898
Renal organic cation transporterNon-inhibitor0.946
CYP450 2C9 substrateNon-substrate0.877
CYP450 2D6 substrateNon-substrate0.8047
CYP450 3A4 substrateSubstrate0.665
CYP450 1A2 substrateNon-inhibitor0.7471
CYP450 2C9 inhibitorNon-inhibitor0.7401
CYP450 2D6 inhibitorNon-inhibitor0.8259
CYP450 2C19 inhibitorNon-inhibitor0.6898
CYP450 3A4 inhibitorInhibitor0.5291
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8482
Ames testNon AMES toxic0.5605
CarcinogenicityNon-carcinogens0.8098
BiodegradationNot ready biodegradable0.9966
Rat acute toxicity2.7064 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9196
hERG inhibition (predictor II)Inhibitor0.6147
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentOligopeptides
Alternative ParentsCyclic peptides / Aminoglycosides / Phenolic glycosides / Leucine and derivatives / N-acyl-alpha amino acids and derivatives / Alpha amino acid amides / Diarylethers / Disaccharides / O-glycosyl compounds / 1-hydroxy-2-unsubstituted benzenoids
SubstituentsAlpha-oligopeptide / Aminoglycoside core / Cyclic alpha peptide / Phenolic glycoside / Leucine or derivatives / N-acyl-alpha amino acid or derivatives / Alpha-amino acid amide / O-glycosyl compound / Glycosyl compound / Disaccharide
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptorsglycopeptide (CHEBI:71229 )
Drug created on March 19, 2008 10:29 / Updated on June 24, 2017 13:25